'Most Impressive' PFS Ever Seen in Midgut NET

September 28, 2015

Patients with midgut neuroendocrine tumors (NETs) who progress on standard treatment with the somatostatin analogue octreotide have few treatment options, but they may soon have a new one — a radiopharmaceutical that appears to deliver a very long-lasting benefit.

The investigative radiopharmaceutical "appears to be a major advance" for this patient population, said the lead investigator Philippe Ruszniewski, MD, head of gastroenterology-pancreatology at Beaujon Hospital in Clichy, France.

Read the full story.